Cargando…

Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer

The Prostate Health Index (phi) has been FDA approved for decision-making regarding prostate biopsy. Phi has additionally been shown to positively correlate with tumor volume, extraprostatic disease and higher Gleason grade tumors. Here we describe a case in which an elevated phi encouraged biopsy o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andreas, Darian, Tosoian, Jeffrey J., Landis, Patricia, Wolf, Sacha, Glavaris, Stephanie, Lotan, Tamara L., Schaeffer, Edward M., Sokoll, Lori J., Ross, Ashley E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4909527/ https://www.ncbi.nlm.nih.gov/pubmed/27335798 http://dx.doi.org/10.1016/j.eucr.2016.04.012

Ejemplares similares

Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance
por: Tosoian, Jeffrey J., et al.
Publicado: (2017)

USE OF THE PROSTATE HEALTH INDEX FOR DETECTION OF PROSTATE CANCER: RESULTS FROM A LARGE ACADEMIC PRACTICE
por: Tosoian, Jeffrey J., et al.
Publicado: (2017)

Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies
por: Salles, Daniela C., et al.
Publicado: (2021)

Nonspecific Presentation of a Multiloculated Prostatic Abscess After Transurethral Prostatic Biopsy for Elevated Prostate-specific Antigen Level
por: Gandhi, Nilay M., et al.
Publicado: (2014)

Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance
por: Kim, Hyung L., et al.
Publicado: (2018)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

Doubling of Decipher Biopsy Genomic Score Is Related to Disease Reclassification on Subsequent Surveillance Biopsy but Not Adverse Features on Radical Prostatectomy
por: Ghabili, Kamyar, et al.
Publicado: (2021)

Step-by-Step: Fusion-guided prostate biopsy in the diagnosis and surveillance of prostate cancer
por: Nassiri, Nima, et al.
Publicado: (2019)

Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
por: White, Jay, et al.
Publicado: (2017)

Metastatic Prostate Cancer Diagnosed by Bone Marrow Aspiration in an Elderly Man Not Undergoing PSA Screening
por: Alam, Ridwan, et al.
Publicado: (2017)

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
por: Albers, Peter, et al.
Publicado: (2020)

PTEN Status Assessment in the Johns Hopkins Active Surveillance Cohort
por: Tosoian, Jeffrey J., et al.
Publicado: (2018)

MyProstateScore in men considering repeat biopsy: validation of a simple testing approach
por: Tosoian, Jeffrey J., et al.
Publicado: (2022)

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
por: Ross, Ashley E., et al.
Publicado: (2017)

Association of Tumor Infiltrating T-cell Density with Molecular Subtype, Racial Ancestry and Clinical Outcomes in Prostate Cancer
por: Kaur, Harsimar B., et al.
Publicado: (2018)

Prediction of Grade Reclassification of Prostate Cancer Patients on Active Surveillance through the Combination of a Three-miRNA Signature and Selected Clinical Variables
por: Gandellini, Paolo, et al.
Publicado: (2021)

Comparison of MRI/US Fusion Targeted Biopsy and Systematic Biopsy in Biopsy-Naïve Prostate Patients with Elevated Prostate-Specific Antigen: A Diagnostic Study
por: Huang, Chen, et al.
Publicado: (2022)

PSA and Beyond: The Past, Present, and Future of Investigative Biomarkers for Prostate Cancer
por: Tosoian, Jeffrey, et al.
Publicado: (2010)

Beyond PSA: The Role of Prostate Health Index (phi)
por: Ferro, Matteo, et al.
Publicado: (2020)

PHI density prospectively improves prostate cancer detection
por: Stephan, Carsten, et al.
Publicado: (2021)

Clinical and pathologic factors predicting reclassification in active surveillance cohorts
por: Sierra, Pablo S., et al.
Publicado: (2018)

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
por: Osses, Daniël F., et al.
Publicado: (2020)

Impact of bilateral biopsy-detected prostate cancer on an active surveillance population
por: Wang, Jonathan H., et al.
Publicado: (2019)

Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs
por: Tomer, Anirudh, et al.
Publicado: (2019)

Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml
por: Ferro, Matteo, et al.
Publicado: (2013)

PTEN Loss is Associated with Upgrading of Prostate Cancer from Biopsy to Radical Prostatectomy
por: Lotan, Tamara L., et al.
Publicado: (2014)

Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer
por: Kobayashi, Hiroaki, et al.
Publicado: (2017)

Iatrogenic Extraprostatic Extension of Prostate Cancer From a Needle Biopsy
por: Johnson, Michael H., et al.
Publicado: (2015)

Sox9 is required for prostate development and prostate cancer initiation
por: Huang, Zhenhua, et al.
Publicado: (2012)

Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers
por: Lotan, Tamara L., et al.
Publicado: (2017)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

The use of prostate MR for targeting prostate biopsies
por: Kelley, R. Phelps, et al.
Publicado: (2019)

Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma
por: Tsai, Harrison K., et al.
Publicado: (2017)

Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance
por: Sandler, Kiri, et al.
Publicado: (2015)

Risk of progression following a negative biopsy in prostate cancer active surveillance
por: Beckmann, Kerri, et al.
Publicado: (2022)

Biopsy interpretation of the prostate
por: Epstein, Jonathan I.

Prostate biopsy interpretation
por: Epstein, Jonathan I.

Role of Prophylactic Antibiotics in Transperineal Prostate Biopsy: A Systematic Review and Meta-analysis
por: Basourakos, Spyridon P., et al.
Publicado: (2022)

Surveillance prostate biopsy utilizing piflufolastat F 18-PET/CT targeting in the intact prostate – A case report
por: Grossman, Tim, et al.
Publicado: (2023)

Incidental finding of extramammary Paget's disease during active surveillance for early‐stage prostate cancer in a prostate biopsy
por: Fujiwara, Kengo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7lqbc9jkbbr2e5rau0ek75qvj9